US Patent Issued to New York University on Dec. 9 for "Targeting SARS-CoV-2 viral-immune interaction for COVID-19 therapy" (New York, California Inventors)

ALEXANDRIA, Va., Dec. 9 -- United States Patent no. 12,491,385, issued on Dec. 9, was assigned to New York University (New York).

"Targeting SARS-CoV-2 viral-immune interaction for COVID-19 therapy" was invented by Jun Wang (New York), Qiao Lu (New York), Jia Liu (New York), Chao Bai Huang (San Leandro, Calif.), Jianbo Dong (Santa Clara, Calif.) and Yue Liu (Foster City, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides compositions and methods for inhibiting the interaction of the SARS-CoV-2 S protein and one or more SARS-CoV-2 S protein interacting protein, and methods of use thereof."

The patent was filed on Sept. 24, 2021, under Application No. 17/484,483.

*For further inform...